This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

A subcutaneous (SC) form of immune anticancer drug that can be administered in 1 to 2 minutes by injection into the skin has ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

Novo Nordisk's Wegovy subcutaneous injection gets approval in Japan for MASH: Osaka, Japan Monday, June 22, 2026, 14:00 Hrs [IST] Sumitomo Pharma Co., Ltd announced that Novo Nord ...

Sanofi's subcutaneous formulation of multiple myeloma drug Sarclisa has been approved in the UK, which will be the first market for the on-body injector (OBI) version of the drug.

The Lenacapavir injections were compared to the current standard of HIV prevention—a pill called Truvada or Descovy taken ...

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...